How many clinical trials are studying Befotertinib?

4 recruiting trials in our tracked data involve Befotertinib.

What conditions is Befotertinib being studied for?

In our tracked recruiting trials, Befotertinib is being studied in trials for Lung cancer, 3-year Disease-free Survival, Adjuvant Drug Therapy.

Recruiting trials

Conditions studied

US states with sites

Countries

Phase 2 3 Phase 4 1

Condition	Trials
Lung cancer · Befotertinib for Lung cancer	4
3-year Disease-free Survival	1
Adjuvant Drug Therapy	1
EGFR	1
EGFR G719X	1
EGFR L861Q	1
EGFR S768I	1
NSCLC	1
NSCLC (Non-small Cell Lung Cancer)	1
Non-small Cell Lung Cancer Metastatic	1

Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
NCT06561620 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
NCT06517953 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
NCT06863506 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
NCT07181499 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations